The Gouverneur Breast & Ovarian Cancer Fund is a community non-profit. Our mission is to alleviate some of the financial burdens patients face during their treatment, allowing them to focus on recovery and healing. Your support goes directly to assist ne
The Gouverneur Breast & Ovarian Cancer Fund is a community non-profit. Our mission is to alleviate some of the financial burdens patients face during their treatment, allowing them to focus on recovery and healing. Your support goes directly to assist ne
The Gouverneur Breast & Ovarian Cancer Fund is a community non-profit. Our mission is to alleviate some of the financial burdens patients face during their treatment, allowing them to focus on recovery and healing. Your support goes directly to assist ne
Ovarian cancer (OvCa), while accounting for only 3% of all women’s cancer, is the fifth leading cause of cancer death among women. One of the most significant obstacles to successful OvCa treatment is chemoresistance. The current lack of understanding of the driving mechanisms underlying chemoresi...
The Pink Fund www.thepinkfund.org During and after treatment for breast cancer, patients can experience significant financial hardship as medical bills mount and their income shrinks. The Pink Fund offers short-term financial aid to patients who lost significant income during treatment so they can ...
FULL PAPER British Journal of Cancer (2013) 108, 1732–1742 | doi: 10.1038/bjc.2013.141 Keywords: ovarian cancer; hereditary; BRCA1; BRCA2; genomic alteration DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas M M Kamieniak1, I Mun˜ ...
The global ovarian cancer market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.1 Billion by 2032, exhibiting a growth rate (CAGR) of 10.09% during 2024-2032.The rising incidence of ovarian cancer cases, the emergence of personalized medi...
The objective of this study was to evaluate the status of MYC and PVT1, which are frequently amplified in malignant tumors, and to assess their biological features according to histological subtypes in early-stage epithelial ovarian cancer (EOC). Methods Formalin-fixed and paraffin-embedded (FFPE)...
Cancer Res., 6 (1946), pp. 578-582 View in ScopusGoogle Scholar [13] C.J. Guigon, N. Coudouel, S. Mazaud-Guittot, M.G. Forest, S. Magre Follicular cells acquire sertoli cell characteristics after oocyte loss Endocrinology, 146 (2005), pp. 2992-3004, 10.1210/en.2005-0045 View...
In 2023, the final PAOLA-1 trial (NCT02477644) survival data were published documenting the benefits of therapy consisting of olaparib plus bevacizumab for patients with advanced ovarian cancer (AOC) as a function of molecular status. In light of these new data, the present study was conducted ...